Functional Electrical Stimulation (FES) and Neuromuscular Electrical Stimulation (NMES) Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Iowa policy alerts
Know when Blue Cross Blue Shield - Iowa releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs the medical necessity and coverage stance for use of FES and NMES devices for rehabilitation (e.g., standing/ambulation after spinal cord injury and prevention/treatment of disuse atrophy) for Blue Cross Blue Shield - Iowa members.
No material clinical or coverage changes in this revision.
Coverage Criteria and Clinical Indications
FES (Parastep) Coverage
Covered when ALL of the following are met
Although Parastep has FDA premarket approval for selected SCI patients, available evidence consists primarily of case series with limited long-term compliance or demonstrated benefit for ADLs/QOL.
NMES — Medically Necessary Criteria for Disuse Atrophy
NMES may be considered medically necessary when ANY of the following specific clinical situations with intact nerve supply are met and documented:
Intact nerve supply to the target muscle required.
Intact nerve supply to the target muscle required.
Intact nerve supply to the target muscle required.
Intact nerve supply to the target muscle required.
NMES — Investigational / Not Covered Indications
NMES is considered investigational for indications when the medically necessary criteria above are not met, including but not limited to:
List is non-exhaustive; investigational when medical necessity criteria (intact innervation and listed scenarios) are not satisfied.
Evidence insufficient to determine effects on net health outcomes for these indications.
NICE guidance specifically recommends NMES should not be offered for knee OA due to insufficient evidence.
Functional Electrical Stimulation (FES) for Ambulation
Covered when ALL of the following are met
Candidates are generally individuals with SCI at segments commonly between T4 and T12 (Parastep PMA indicates C6 to T12); device use is intended only after a prescribed training period and with rehabilitation support; devices are not intended as alternatives to a wheelchair and provide, at best, limited, short-term ambulation.
Neuromuscular Electrical Stimulation (NMES) for Rehabilitation
Covered when ALL of the following are met
Intact nerve supply to the target muscle is required; effectiveness evidence varies by indication (e.g., RCT/meta-analysis support quadriceps strength improvement after TKA; evidence for NMES+exercise in knee OA is insufficient).
Summary coverage-relevant evidence statements
Evidence-based conclusions reported in the document:
Carvalho et al (2023) concluded insufficient evidence; included small trials.
Peng et al (2021) included 9 RCTs (691 patients); stimulation frequency 30-100 Hz.
Wang et al (2023) included 46 studies (3,346 patients) with regional bias and limited blinding.
Oh et al (2023) and Ohnishi et al report modest positive effects but recommend larger, higher-quality studies.
Coverage logic and indication-specific summaries
Coverage considerations should reflect the following evidence- and guidance-based logic:
Evidence is mixed; some RCTs show benefit but are limited by small sizes and heterogeneity.
Recommend requiring documentation of governance/consent/research participation when used outside established contexts.
Takino et al (2023) showed reduced %ΔIKES at POD7 with NMES versus sham; further standardization needed.
Systematic reviews report insufficient evidence of benefit.
Carvalho et al and NICE conclusions cited.
Functional Electrical Stimulation (FES) devices billed with HCPCS code E0770 are classified in this policy as home exercise equipment and are generally excluded from coverage (noncovered benefit), regardless of the clinical indication.
The policy states that FES systems are not intended to substitute for a wheelchair or serve as a means for independent community ambulation; these systems offer, at best, limited and typically short-term ambulation and are not recommended for routine community ambulation or as an alternative to a wheelchair.
Although the document does not list explicit exclusions for specific populations, it notes evidence limitations in certain groups — for example, a small retrospective study of chronic low back pain did not demonstrate benefit and systematic reviews for other conditions report insufficient or mixed evidence. These limitations mean that support for NMES in some populations (e.g., chronic low back pain) is limited, though not explicitly excluded.
The National Institute for Health and Care Excellence (NICE) guidance cited in the policy recommends that NMES should not be offered for knee osteoarthritis because the evidence is insufficient and inconsistent to demonstrate benefit.
No additional explicit coverage criteria are stated in the provided policy portion beyond the described medically necessary and investigational statements and the device/coding notes in other sections of the document.
Overall the policy stance is mixed: the Parastep® FES ambulation system is considered investigational and NMES is investigational for indications not meeting the specified medical necessity criteria; conversely, NMES may be considered medically necessary for defined disuse-atrophy scenarios when documentation of intact innervation and stated clinical conditions is provided.
A recent systematic review and meta-analysis concluded that adding NMES to exercise for patients with knee osteoarthritis did not produce superior improvements in patient-reported outcome measures (pain, stiffness, function) compared with exercise alone; therefore the evidence is insufficient to support routine coverage of NMES combined with exercise for KOA symptom management.
The meta-analysis of trials in knee osteoarthritis found no additional benefit of NMES plus exercise over exercise alone on PROMs; the authors concluded NMES + exercise was not superior to exercise alone for patient-reported outcomes in KOA.
The policy highlights that evidence is insufficient to support NMES for stable severe COPD and several other indications reviewed; therefore routine coverage for these indications without clear functional benefit and supporting documentation is not supported.
The provided policy excerpts do not contain separate, explicit 'not medically necessary' declarations beyond the investigational classifications and exclusions already summarized in other sections.
Coding and Billing
| E0770 | functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified |
| Parastep® (device) | Parastep Ambulation System — noninvasive FES device with FDA approval (C6 to T12 indication) |
| QB1 System | Device combining NMES and TENS; used for quadriceps activation and pain management (listed among devices) |
| Biomove; Geko; Guardian Dysphagia; Guardian Aspire 2; M‑Wave; VitalStim; RS‑2m; RS‑4i; RS‑4m; Empi Phoenix; Flex‑MT Plus; Kneehab XP; NexWave | Devices listed in document as NMES or NMES/TENS devices |
| A4560 | Neuromuscular electrical stimulator (nmes), disposable, replacement only. |
| E0744 | Neuromuscular stimulator for scoliosis. |
| E0745 | Neuromuscular stimulator, electronic shock unit. |
| E0764 | Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program (ParaStep®). |
| E1399 | Miscellaneous durable medical equipment. |
| No codes listed |
Prior Authorization, Documentation, and Provider Responsibilities
Prior approval not applicable
Not applicable — this policy states that prior approval is not required.
Prior authorization for Parastep® ambulation
Obtain prior authorization reflecting that Parastep® is intended only for appropriately selected skeletally mature spinal cord injured patients (PMA indication C6 to T12) after prescribed physical therapy and rehabilitation training.
- Parastep® is approved to enable skeletally mature SCI patients (C6 to T12) to stand and attain limited ambulation after a prescribed period of physical therapy training [[see cited chunks]]
No explicit prior‑authorization codes specified
The document does not list specific procedure or billing codes that require prior authorization; supporting clinical trial reports and device parameters may be requested to substantiate medical necessity.
Recommend prior authorization for conditional/experimental NMES uses
Consider requiring prior authorization for NMES uses that are conditional or supported only by limited/conditional guidance (e.g., shoulder pain, foot drop, spasticity, dysphagia) to verify indication and documentation.
- Professional guidance notes NMES may be reasonable/conditional for some stroke-related and mobility indications but advises limited use for dysphagia without governance.
Document prior therapy failure / inability for NMES
Document failure to respond to or inability to participate in physical therapy when requesting NMES for disuse atrophy or postoperative indications, as NMES is considered medically necessary in those circumstances.
- NMES is medically necessary for disuse atrophy when there is documented failure to respond to or inability to participate in physical therapy for listed scenarios (e.g., post‑TKA, post‑THA, immobilization).
Conservative therapy should be attempted and documented
Attempt and document conventional rehabilitation/physical therapy prior to device‑based NMES/FES for rehabilitation goals except where criteria specify use prior to initiation of PT (e.g., immediate post‑THA until PT begins).
- Standard of care (conventional rehabilitation/physical therapy) should generally be attempted and documented before NMES/FES is used as a device‑based intervention.
No specified step‑therapy protocol
No step therapy protocols are specified in this policy; the document does not define a required stepwise protocol.
Consider NMES as alternative or adjunct; document alternatives
Consider NMES as an alternative or adjunct in scenarios recommended by guidance (for example, as an alternative to an AFO for foot drop) and document prior conservative therapies and established alternatives.
- Guidance (AHA/ASA) states NMES is reasonable to consider as an alternative to an AFO for foot drop and may be reasonable as an adjunct in select post‑stroke indications.
Device use and training documentation
For Parastep® use, document that patients completed at least 32 training sessions and note device donning time; note NMES devices are externally affixed with electrodes per rehabilitative protocols.
- Parastep®: at least 32 training sessions required; device can be donned in less than 10 minutes.
- NMES devices: affixed externally with electrodes and used according to rehabilitation protocols.
Document clinical indication and intact innervation
Document the clinical indication supporting NMES/FES requests — injury, surgical immobilization, or a diagnosed condition causing clinically significant muscle atrophy (e.g., stroke, cerebral palsy, CHF).
- NMES indications require intact nerve supply and a documented injury/immobilization or condition causing muscle atrophy as specified in policy.
Typical documentation elements to include
Include typical documentation elements when submitting NMES/FES requests: indication, treatment parameters (frequency, pulse width, duration), concurrent therapy, outcome measures, and adverse events or lack thereof.
- Common outcome measures cited: VAS/NRS, WOMAC, strength tests, TUG, 6MWT, KOOS, FOIS, PAS, VFSS.
- Report treatment parameters used and concurrent rehabilitation interventions.
Dysphagia‑specific documentation and governance
When NMES is used for dysphagia outside established indications, include documentation of patient selection, treatment indication, informed consent, and participation in clinical governance or research per NICE recommendations.
- NICE recommends special arrangements for clinical governance, consent, and audit or research for transcutaneous NMES in oropharyngeal dysphagia.
Required coding documentation and Place of Service
Report provider services with appropriate CPT, HCPCS, Revenue, and ICD diagnosis codes and include Place of Service (outpatient, home‑based) and Type of Service = Durable Medical Equipment when applicable.
FES device (E0770) exclusion — high denial risk
FES devices coded as E0770 are considered home exercise equipment and are generally excluded from coverage; requests for E0770 are at high risk of denial as a noncovered benefit.
- E0770 functional electrical stimulator is described as home exercise equipment and generally excluded regardless of indication.
Investigational indication — Parastep® and many NMES uses
Expect denial risk for Parastep® ambulation (FES) as the document considers Parastep investigational and states evidence is insufficient to demonstrate improvement in net health outcomes.
- Coverage stance: Parastep® Ambulation System is considered investigational; evidence consists mainly of case series with no demonstrated long‑term health outcome improvements.
Evidence and durability concerns may prompt denial
Provide documentation of long‑term functional benefit and patient compliance for FES ambulation; lack of long‑term compliance data or demonstrated ADL/QOL improvement may lead to denial.
- Studies report limited, short‑term ambulation and no long‑term compliance data; improved ADLs/QOL not demonstrated.
Evidence limitations may trigger medical‑necessity review
Be prepared for additional review or denial when evidence is limited, of low quality, or from small studies; the policy notes such limitations may prompt medical‑necessity review.
- Systematic reviews and RCTs are frequently small or heterogeneous; submit robust clinical rationale and outcomes to address these limitations.
NICE: dysphagia NMES only with special governance — risk if absent
For transcutaneous NMES for oropharyngeal dysphagia, ensure special arrangements for clinical governance, consent, and audit or research are documented per NICE guidance; absence of these may risk non‑coverage.
- NICE: technology should only be used with special arrangements for clinical governance, consent and audit or research.
Coding‑related denial risk if codes are incorrect or missing
Use appropriate CPT, HCPCS, Revenue, and ICD diagnosis codes when reporting services; failure to use correct codes may result in claim denial.
- Policy explicitly directs reporting with appropriate CPT/HCPCS/Revenue/ICD codes and Place of Service.
Background and Rationale
Functional Electrical Stimulation (FES) applies microprocessor-controlled electrical stimulation to restore functional movements in muscles with damaged or destroyed nerve pathways (for example, enabling standing and stepping in selected spinal cord injured individuals).
Definitions and Device Descriptions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.